ライフサイエンスコーパス: thyroid-stimulating hormone

1 rates, and levels of C-reactive protein and thyroid-stimulating hormone.

2 e exposures under study were associated with thyroid-stimulating hormone.

3 gene, in primary thyroid cells treated with thyroid-stimulating hormone.

4 dine kinetics as seen with recombinant human thyroid-stimulating hormone.

5 f patients, and 12% developed elevated serum thyroid-stimulating hormone.

6 mone (LH), chorionic gonadotropin (hCG), and thyroid-stimulating hormone.

7 of 948 case-control pairs were assessed for thyroid-stimulating hormone.

8 CT after administration of recombinant human thyroid-stimulating hormone.

9 range or slightly decreased concentration of thyroid-stimulating hormone.

10 les should prompt measurement of circulating thyroid-stimulating hormone.

11 alysis to euthyroid participants (defined by thyroid-stimulating hormone 0.4-4.0 mIU/L).

12 ate of (124)I PET/CT after recombinant human thyroid-stimulating hormone (124)I PET/CT as implemented

13 Thyroid-stimulating hormone administration led to a vari

14 We show here that negative regulation of the thyroid-stimulating hormone alpha (TSHalpha) promoter by

15 In contrast, the thyroid-stimulating hormone alpha-subunit (TSH alpha) ge

16 ee negatively regulated genes (the pituitary thyroid-stimulating hormone alpha-subunit [TSH alpha], T

17 us nonhuman hormones we have developed human thyroid stimulating hormone and chorionic gonadotropin a

18 TC risk stratification have emerged, such as thyroid stimulating hormone and molecular markers.

19 of thyroxine, reverse triiodothyronine, and thyroid-stimulating hormone and a decrease in serum trii

20 crease in 3,5,3'-triiodothyronine (T(3)) and thyroid-stimulating hormone and an increase in reverse T

21 Associations of thyroid-stimulating hormone and free thyroxine with the

22 We assessed the association of thyroid-stimulating hormone and FT4 with the risk of SCD

23 to reduced mRNA expression of both pituitary thyroid-stimulating hormone and hypothalamic thyrotropin

24 ct correlation between circulating levels of thyroid-stimulating hormone and NIS expression in vivo w

25 All patients had normal levels of thyroid-stimulating hormone and no other gastrointestina

26 nlarged follicles, in the presence of normal thyroid-stimulating hormone and T4 hormone levels.

27 nce of NCOR1DeltaID, the abnormally elevated thyroid-stimulating hormone and TH levels found in Thrb(

28 hat express both alpha- and beta-subunits of thyroid-stimulating hormone and the transcription factor

29 amily that includes luteinzing hormone (LH), thyroid stimulating hormone, and chorionic gonadotropin.

30 r three analytes (prostate specific antigen, thyroid stimulating hormone, and luteinizing hormone) we

31 era were assayed for thyroid autoantibodies, thyroid-stimulating hormone, and anti-FcepsilonRIalpha a

32 ormone family including luteinizing hormone, thyroid-stimulating hormone, and chorionic gonadotropin.

33 tudy resembles those reported for prolactin, thyroid-stimulating hormone, and free fatty acids.

34 ctin, cortisol, adrenocorticotropic hormone, thyroid-stimulating hormone, and free thyroxine levels.

35 -specific regulation of growth hormone (GH), thyroid-stimulating hormone, and prolactin (PRL) secreti

36 ficient mice, thyrotropin-releasing hormone, thyroid-stimulating hormone, and thyroid hormone are dec

37 As part of the study, plasma selenium, thyroid-stimulating hormone, and total and free T(3) and

38 ty lipoprotein cholesterol, creatine kinase, thyroid-stimulating hormones, and erythrocyte sedimentat

39 ement procedures for serum concentrations of thyroid-stimulating hormone are likewise under developme

40 human fetal pituitary cultures, where GH and thyroid-stimulating hormone are mediated by both SSTR2 a

41 ds of a glycoprotein using recombinant human thyroid-stimulating hormone as a model system.

42 hormone-releasing hormone tests or sensitive thyroid-stimulating hormone assays.

43 Thyroxine, free thyroxine index, and thyroid-stimulating hormone at 6 mo were inversely assoc

44 increase heart weight or decrease pituitary thyroid-stimulating hormone beta (TSHbeta) expression.

45 ligand-dependent negative regulation of the thyroid-stimulating hormone beta (TSHbeta) gene.

46 d repress the alpha glycoprotein subunit and thyroid-stimulating hormone beta promoters.

47 We found that thyroid-stimulating hormone beta subunit (tshb) and type

48 0th and 12th cysteine (Cys88-Cys105 in human thyroid-stimulating hormone beta-subunit (hTSHbeta)) of

49 Growth hormone, prolactin, and thyroid-stimulating hormone beta-subunit expression were

50 ollicle-stimulating hormone beta-subunit and thyroid-stimulating hormone beta-subunit) showed no sign

51 ere was selective expression of the gene for thyroid-stimulating hormone beta; detection of the thyro

52 5% CI: -0.092, -0.013), and increasing log10 thyroid-stimulating hormone (beta = 0.071; 95% CI: 0.008

53 erse events were observed, and elevations of thyroid-stimulating hormone, blood urea nitrogen, and cr

54 r pituitary cells that express the genes for thyroid-stimulating hormone but not in the cells that ex

55 s bind to the receptor and mimic its ligand, thyroid stimulating hormone, causing the characteristic

56 on, growth hormone, luteinizing hormone, and thyroid-stimulating hormone cells and tumors had the hig

57 marrow, liver, and renal function; and serum thyroid-stimulating hormone concentration lower than 0.5

58 tween examinations, age, sex, baseline serum thyroid-stimulating hormone concentration, and cystic co

59 mmendations are based on the degree to which thyroid-stimulating hormone concentrations have deviated

60 an thyroid cells by the activation of serum, thyroid-stimulating hormone/cyclic AMP, or epidermal gro

61 iciency (12.5%), precocious puberty (12.2%), thyroid-stimulating hormone deficiency (9.2%), and thyro

62 rated that FRTL-5 cells express megalin in a thyroid-stimulating hormone-dependent manner.

63 unting for persistently reduced secretion of thyroid-stimulating hormone despite low plasma thyroid h

64 leptin-induced thyrotropin-releasing hormone/thyroid-stimulating hormone expression.

65 Thyroid stimulating hormone, free thyroxine, 25-hydroxy

66 Rotterdam Study with data available on TSH (thyroid-stimulating hormone), FT4 (free thyroxine) and g

67 agnosed based on baseline blood sampling for thyroid stimulating hormone, gonadotropin, and prolactin

68 Thyroid stimulating hormone (h(2)=0.58, P=2 x 10(-)(5))

69 ein, low-density lipoprotein, triglycerides, thyroid stimulating hormone, homocysteine, C-reactive pr

70 idines that bind with high-affinity to human thyroid stimulating hormone (hTSH) were isolated from a

71 modeling we have designed recombinant human thyroid-stimulating hormone (hTSH) analogs with increase

72 The human thyroid-stimulating hormone (hTSH) subunits alpha and be

73 design of experiments (DOE) optimization for thyroid-stimulating hormone immunoassays, varying (1) th

74 of (131)I within lesions, and of the role of thyroid-stimulating hormone in stimulating the sodium-io

75 s of serum thyroxin, and augmented levels of thyroid-stimulating hormone in the pituitary gland), fea

76 il domain of STRN and to a kinase-dependent, thyroid-stimulating hormone-independent proliferation of

77 ytes, suggesting that a relevant part of the thyroid-stimulating hormone-induced proliferation signal

78 mplexes for sulfated glycopeptides of equine thyroid stimulating hormone is compared with information

79 We have previously shown that thyroid-stimulating hormone is required, but not suffici

80 Hematocrit level, thyroid stimulating hormone level, autoimmune antibody l

81 hyroid hormone withdrawal to achieve a serum thyroid-stimulating hormone level in excess of 30 microI

82 t hypothyroxinemia without markedly lowering thyroid stimulating hormone levels, thus creating a bioc

83 proximately 50-80%) and profoundly increased thyroid-stimulating hormone levels ( approximately 800-1

84 Tg-BRAF2 and Tg-BRAF3 mice had increased thyroid-stimulating hormone levels (>7- and approximatel

85 e interval, 1.68-3.47 per 1 ng/dL) and lower thyroid-stimulating hormone levels (hazard ratio, 0.92;

86 rb(PV/PV) mice exhibit highly elevated serum thyroid-stimulating hormone levels and increased TH.

87 suggested that subclinical abnormalities in thyroid-stimulating hormone levels are associated with d

88 For subclinical hypothyroidism (based on thyroid-stimulating hormone levels of 4.1 to 11.0 mIU/L)

89 s aged 65 years or older with baseline serum thyroid-stimulating hormone levels were enrolled in 1989

90 c variant in GNAS associating with increased thyroid-stimulating hormone levels when maternally inher

91 Long-term, 5 patients developed elevated thyroid-stimulating hormone levels, 5 were diagnosed wit

92 blood cell count, C-reactive protein levels, thyroid-stimulating hormone levels, and thyroid peroxida

93 ished cAMP-Epac-mediated Rap1 activation and thyroid-stimulating hormone-mediated cell proliferation,

94 aled that activation of Epac is required for thyroid-stimulating hormone or cAMP stimulation of DNA s

95 ts from the Rotterdam Study >/=45 years with thyroid-stimulating hormone or free thyroxine (FT4) meas

96 tected no changes in serum concentrations of thyroid-stimulating hormone or free tri-iodothyronine, f

97 which competitively inhibits the binding of thyroid-stimulating hormone or the human autoantibody to

98 The elevation of thyroid-stimulating hormone, or thyrotropin (TSH), that

99 ormone levels and inappropriate thyrotropin (thyroid-stimulating hormone, or TSH) production.

100 after therapy was associated with response (thyroid-stimulating hormone, P2 =.01; free T4, P2 =.0049

101 luded left ventricular dysfunction, elevated thyroid stimulating hormone, palmar-plantar erythrodyses

102 nce to suggest that high doses that suppress thyroid stimulating hormone prevent disease recurrence i

103 l nervous system (locomotion) and endocrine (thyroid-stimulating hormone, prolactin and insulin secre

104 ith lung metastases when a recombinant human thyroid-stimulating hormone protocol is used.

105 cium, intact parathyroid hormone (iPTH), and thyroid stimulating hormone; psychological symptom inven

106 had no effect on fasting-induced changes in thyroid-stimulating hormone pulsatility, thyroid and IGF

107 ecretion, as well as luteinizing hormone and thyroid-stimulating hormone pulsitility.

108 Genetic associations of the thyroid stimulating hormone receptor (TSHR) gene with GD

109 s12101255 and rs12101261) in intron 1 of the thyroid stimulating hormone receptor (TSHR) gene.

110 The thyroid stimulating hormone receptor (TSHR) is a G prote

111 onal outcome is predicted for over a hundred thyroid stimulating hormone receptor (TSHR) mutations, a

112 The thyroid stimulating hormone receptor (TSHR) represents t

113 The roles of the thyroid stimulating hormone receptor and cellular and hu

114 nformations that were created by joining the thyroid stimulating hormone receptor exoloops constraine

115 sociated with human brittle bone disease and thyroid stimulating hormone receptor hyperactivity.

116 ceptor/follicle stimulating hormone receptor/thyroid stimulating hormone receptor were mapped using e

117 verexpression and showed decreased levels of thyroid stimulating hormone receptor-stimulating Abs and

118 s II-restricted autoantibody response to the thyroid stimulating hormone receptor.

119 duction of stimulating autoantibodies to the thyroid-stimulating hormone receptor (TSHR) (TSAbs) that

120 Tg and the thyroid-stimulating hormone receptor (TSHR) are targets

121 Thyroid-stimulating hormone receptor (TSHR) expression i

122 The thyroid-stimulating hormone receptor (TSHR) is a G prote

123 high homology with LHCGR, we predicted that thyroid-stimulating hormone receptor (TSHR) might be act

124 m because of autoantibodies that bind to the thyroid-stimulating hormone receptor (TSHR) on the thyro

125 Thyroid-stimulating hormone receptor (TSHR) plays a cent

126 tors (luteinizing hormone receptor (LHR) and thyroid-stimulating hormone receptor (TSHR)) was expecte

127 The thyrotropin receptor, also known as the thyroid-stimulating hormone receptor (TSHR), is the prim

128 The genes for thyroid-stimulating hormone receptor (TSHR), the SOX11 t

129 pin receptor (LHCGR) and the closely related thyroid-stimulating hormone receptor (TSHR), was fundame

130 odium iodide symporter, thyroperoxidase, and thyroid-stimulating hormone receptor and to a moderate a

131 levels and coordinating the expression of a thyroid-stimulating hormone receptor antagonist (TSHAnta

132 dies to thyroperoxidase or thyroglobulin, or thyroid-stimulating hormone receptor antibodies (TRAbs),

133 to the agonist and antagonist activities of thyroid-stimulating hormone receptor autoantibodies.

134 gion or in p10 can inhibit activation of the thyroid-stimulating hormone receptor by autoantibodies.

135 Thyroid-stimulating hormone receptor expressing cells al

136 Expression of functional thyroid-stimulating hormone receptor in the skin may hav

137 We found significant expression of the thyroid-stimulating hormone receptor mRNA in cultured ke

138 at these tissues share a common antigen: the thyroid-stimulating hormone receptor protein.

139 The presence of thyroid-stimulating hormone receptor was confirmed by no

140 r was confirmed by northern analyses and the thyroid-stimulating hormone receptor was found to be fun

141 roid differentiation markers, thyroglobulin, thyroid-stimulating hormone receptor, thyroid peroxidase

142 o be linked to photoperiod and reproduction (thyroid-stimulating hormone receptor, TSHR).

143 ations at Ser-281 in the hinge region of the thyroid-stimulating hormone receptor, we mutated the con

144 unit GPA2, serves as a second ligand for the thyroid-stimulating hormone receptor.

145 uction of stimulating antibodies against the thyroid-stimulating hormone receptor.

146 thyroid, but in states of hyperactivation of thyroid-stimulating hormone receptors (TSHRs), patients

147 tion mutants of luteinizing hormone (LH) and thyroid-stimulating hormone receptors found in patients

148 suppressive if suppression was documented by thyroid-stimulating hormone-releasing hormone tests or s

149 We now report that thyroid-stimulating hormone represses mitogen-activated

150 r production of growth hormone, prolactin or thyroid-stimulating hormone, resulting in dysmorphogenes

151 neck dissection and use of recombinant human thyroid stimulating hormone (rhTSH) for (1)(3)(1)I radio

152 atients with injections of recombinant human thyroid-stimulating hormone (rhTSH) and thyroid hormone

153 ormone withdrawal (THW) or recombinant human thyroid-stimulating hormone (rhTSH) injections before (1

154 current findings of using recombinant human thyroid-stimulating hormone (rhTSH, also known as Thyrog

155 tion for remnant ablation (recombinant human thyroid-stimulating hormone [rhTSH] vs. traditional thyr

156 contemporary use of recombinant thyrotropin (thyroid-stimulating hormone) (rTSH) to prepare patients

157 inopathy was cost-effective as compared with thyroid-stimulating hormone screening.

158 Hyperthyroidism due to thyroid-stimulating hormone-secreting tumors accounts fo

159 sium channel subunits KCNQ1 and KCNE2 form a thyroid-stimulating hormone-stimulated, constitutively a

160 Thyroid-stimulating hormone stimulates proliferation thr

161 rum biomarkers of thyroid function including thyroid-stimulating hormone, thyroglobulin, total and fr

162 (triiodothyronine (T3) and thyroxine (T4)), thyroid-stimulating hormone, thyroid peroxidase antibodi

163 g RRA after preparation by recombinant human thyroid-stimulating hormone (thyrotropin; TSH) over the

164 These compounds, as well as thyroid-stimulating hormone, total thyroxine, and free t

165 The 11 analytes included 9 hormones (ie, thyroid-stimulating hormone, total thyroxine, total trii

166 n, stimulates DNA synthesis in quiescent and thyroid-stimulating hormone-treated thyrocytes.

167 sessable patients have developed an elevated thyroid-stimulating hormone; treatment with thyroxine ha

168 petitive and competitive immunoassays, using thyroid stimulating hormone (TSH) and 17beta-estradiol (

169 t AKAP121 protein expression is regulated by thyroid stimulating hormone (TSH) and cAMP.

170 d (HPT) axis maintains circulating levels of thyroid stimulating hormone (TSH) and thyroid hormone (T

171 itu modification of pCB films with antihuman thyroid stimulating hormone (TSH) IgG molecules and the

172 GH), adrenocorticotropic hormone (ACTH), and thyroid stimulating hormone (TSH) in both normal and tum

173 nsible for deficiencies of GH, prolactin and thyroid stimulating hormone (TSH) in Snell and Jackson d

174 The established function of thyroid stimulating hormone (TSH) is to promote thyroid

175 tion of autoantibodies against receptors for thyroid stimulating hormone (TSH) on thyroid epithelial

176 utoantibody and its Fab fragment bind to the thyroid stimulating hormone (TSH) receptor (TSHR) with h

177 15 months; necropsy was performed and serum thyroid stimulating hormone (TSH) was measured.

178 It has long been known that thyroid stimulating hormone (TSH), a central component o

179 k factors according to genetically predicted thyroid stimulating hormone (TSH), free thyroxine (FT4)

180 ions of total testosterone, prolactin (PRL), thyroid stimulating hormone (TSH), free triiodothyronine

181 Thyroid Stimulating Hormone (TSH), T3 and T4 levels were

182 ng effect depends on tanycyte sensitivity to thyroid stimulating hormone (TSH), which is dramatically

183 The euthyroid state was defined as thyroid-stimulating hormone (TSH) 0.45 to 4.49 mIU/L, an

184 yroidism is defined as an elevation in serum thyroid-stimulating hormone (TSH) above the upper limit

185 roid hormone associated with nonsuppressible thyroid-stimulating hormone (TSH) and impaired growth.

186 value and correlated to the available serum thyroid-stimulating hormone (TSH) and thyroid peroxidase

187 we demonstrate that GLIS3 acts downstream of thyroid-stimulating hormone (TSH) and TSH receptor (TSHR

188 In this issue of Cell, identify thyroid-stimulating hormone (TSH) as an important regula

189 pha-subunit (alphaSU)-null mice that develop thyroid-stimulating hormone (TSH) cell hyperplasia with

190 ha (TRalpha(o/o)) that maintain normal serum thyroid-stimulating hormone (TSH) concentration despite

191 hyroidism, and is usually defined as a serum thyroid-stimulating hormone (TSH) concentration greater

192 ne (T4) and T3, and modest or no increase in thyroid-stimulating hormone (TSH) concentration.

193 Thyroid-stimulating hormone (TSH) controls thyroid growt

194 The cumulative incidence of GHD, thyroid-stimulating hormone (TSH) deficiency, adrenocort

195 streamlined, we evaluated the time course of thyroid-stimulating hormone (TSH) elevation after total

196 Since thyroid-stimulating hormone (TSH) exerts an inductor eff

197 ed sensitive assays for thyroid hormones and thyroid-stimulating hormone (TSH) has increased identifi

198 Thyroid-stimulating hormone (TSH) has long been recogniz

199 RH) in the mediobasal hypothalamus (MBH) and thyroid-stimulating hormone (TSH) in the pituitary.

200 measured free thyroxine (T4), total T4, and thyroid-stimulating hormone (TSH) in women during pregna

201 A 15-min stimulation with thyroid-stimulating hormone (TSH) led to an activation o

202 SCH was defined as a serum thyroid-stimulating hormone (TSH) level of 5.0 to 19.96

203 ted to achieve a normal and suppressed serum thyroid-stimulating hormone (TSH) level, respectively.

204 inical data showing correlations between low thyroid-stimulating hormone (TSH) levels and high bone t

205 Serum thyroxine, T3, and thyroid-stimulating hormone (TSH) levels and pituitary T

206 hyroid function through suppression of serum thyroid-stimulating hormone (TSH) levels and TSH-beta su

207 Controlled treatment studies that used thyroid-stimulating hormone (TSH) levels as an inclusion

208 opeptide that exerts the hormonal control of thyroid-stimulating hormone (TSH) levels as well as neur

209 ities have been uncommon except for elevated thyroid-stimulating hormone (TSH) levels found in approx

210 yroid hormone levels, and none have measured thyroid-stimulating hormone (TSH) levels in neonates.

211 terized by low thyroid hormone (TH) and high thyroid-stimulating hormone (TSH) levels in the serum, i

212 Patients with serum thyroid-stimulating hormone (TSH) levels outside the ref

213 ent were collected, and thyroxine (T(4)) and thyroid-stimulating hormone (TSH) levels were measured a

214 tary adrenocorticotrophic hormone (ACTH) and thyroid-stimulating hormone (TSH) levels were normal, bu

215 elevated serum TH and inappropriately normal thyroid-stimulating hormone (TSH) levels, consistent wit

216 ons were positively associated with maternal thyroid-stimulating hormone (TSH) levels.

217 aracterized by high thyroid hormone (TH) and thyroid-stimulating hormone (TSH) levels.

218 Following analysis of serial thyroid-stimulating hormone (TSH) measurements collected

219 We recently described the direct effects of thyroid-stimulating hormone (TSH) on bone and suggested

220 m implications for the functional reserve of thyroid-stimulating hormone (TSH) production and the TSH

221 al practice: 1) The development of the serum thyroid-stimulating hormone (TSH) radioimmunoassay led t

222 We have shown recently that by acting on the thyroid-stimulating hormone (TSH) receptor (TSHR), TSH n

223 of wild type or N54-alpha(s) along with the thyroid-stimulating hormone (TSH) receptor and adenylyl

224 Use of human FSH/thyroid-stimulating hormone (TSH) receptor chimeras sugg

225 The thyroid-stimulating hormone (TSH) receptor signals via G

226 yrotropin-releasing hormone (TRH) stimulates thyroid-stimulating hormone (TSH) secretion from the ant

227 with controls infused with vehicle, whereas thyroid-stimulating hormone (TSH) secretion was not chan

228 rculating TH levels are tightly regulated by thyroid-stimulating hormone (TSH) secretion within the h

229 hibitor of pituitary growth hormone (GH) and thyroid-stimulating hormone (TSH) secretion, binds to fi

230 oid ablation rate was equivalent for the two thyroid-stimulating hormone (TSH) stimulation methods (t

231 tropin-releasing hormone (TRH) and pituitary thyroid-stimulating hormone (TSH) subunit genes, however

232 Plasma thyroid-stimulating hormone (TSH) was significantly supp

233 Thyroid-stimulating hormone (TSH), a central neuroendocr

234 oid follicular cells, a system that requires thyroid-stimulating hormone (TSH), acting via cAMP, to m

235 d an increase in the pituitary expression of thyroid-stimulating hormone (TSH), an increase in the bl

236 Plasma free T4, thyroid-stimulating hormone (TSH), and 8 am cortisol lev

237 e thyroiditis (AIT), serum concentrations of thyroid-stimulating hormone (TSH), and autoantibodies to

238 ternal serum levels of free thyroxine (FT4), thyroid-stimulating hormone (TSH), and thyroid peroxidas

239 e shown that the anterior pituitary hormone, thyroid-stimulating hormone (TSH), can bypass the thyroi

240 iomarkers, including serum concentrations of thyroid-stimulating hormone (TSH), free thyroxine (FT4),

241 Thyroid-stimulating hormone (TSH), free thyroxine (T(4))

242 A panel of thyroid measures, including thyroid-stimulating hormone (TSH), thyroxine, triiodothy

243 Serum levels of thyroid-stimulating hormone (TSH), total thyroxine (TT4)

244 There is evidence, however, that thyroid-stimulating hormone (TSH), which is low in most

245 Also, thyroid-stimulating hormone (TSH), which is released by

246 thyroidal Na(+)/I(-) symporter expression is thyroid-stimulating hormone (TSH)-dependent and basolate

247 ods and pharmaceuticals, negatively regulate thyroid-stimulating hormone (TSH)-dependent Ca(2+) incre

248 protein levels are dynamically regulated in thyroid-stimulating hormone (TSH)-dependent thyroid cell

249 Thyroid-stimulating hormone (TSH)-induced reduction in l

250 Depletion of LXRs activated thyroid-stimulating hormone (TSH)-releasing hormone (TRH

251 Thyroid-stimulating hormone (TSH)-secreting tumors (TSH-

252 drenocorticotropin hormone (ACTH)-secreting, thyroid-stimulating hormone (TSH)-secreting, and nonfunc

253 to be a primary source of intestine-derived thyroid-stimulating hormone (TSH).

254 evelop PTC rapidly with high levels of serum thyroid-stimulating hormone (TSH).

255 ith total triiodothyronine (T3), free T4, or thyroid-stimulating hormone (TSH).

256 ine (L-T4) along with normalization of serum thyroid-stimulating hormone (TSH).

257 ), Rab1b expression increases in response to thyroid-stimulating hormone (TSH).

258 The thyrotropin [thyroid-stimulating hormone (TSH)] receptor (TSHR) is kn

259 Evidence was presented that thyrotropin [thyroid-stimulating hormone (TSH)]-stimulated persistent

260 e mortality and explore the relation between thyroid-stimulating hormone (TSH; also known as thyrotro

261 Recent studies have identified a role for thyroid-stimulating hormone (TSH; ie, thyrotropin) as an

262 e, heterodimeric glycoprotein hormones, like thyroid-stimulating hormone (TSH; thyrotropin), have onl

263 tal and free triiodothyronine [TT3 and FT3], thyroid-stimulating hormone [TSH], and thyroglobulin [Tg

264 1), alanine aminotransferase (p = 0.035) and thyroid-stimulating hormone values (p = 0.013) than thos

265 [OR] 5.78, 95% CI 2.00-16.67; p=0.001), and thyroid stimulating hormone was increased on average by

266 in the ISP56 group, and the concentration of thyroid-stimulating hormone was higher in the ISP90 grou

267 Thyroid-stimulating hormone was measured in sera obtaine

268 At the last follow-up visit, thyroid-stimulating hormone was similar in both groups.

269 Thyroid-stimulating hormone was suppressed in patients g

270 a (free thyroxine </=10th percentile, normal thyroid-stimulating hormone) was associated with an incr

271 , free thyroxine, free triiodothyronine, and thyroid-stimulating hormone were measured in 1996 (n = 9

272 id cancer (DTC) may be prepared using either thyroid-stimulating hormone withdrawal (THW) or recombin